Roundup: Lunit INSIGHT CXR comes to Brazil and more briefs
LifeSemantics teases pulmonary rehabilitation DTx
South Korean digital health company LifeSemantics is launching its digital therapeutics product that helps with the pulmonary rehabilitation of people with COPD.
The Redpill Breath DTx helps users self-rehabilitate their respiratory functions at home. It monitors their oxygen saturation and walking performance in real time, sends text alerts in case of emergency or lack of exercise during rehabilitation sessions, and transmits health data to their medical team also in real time. It can also adjust their exercise level depending on the user’s physical condition using a metronome.
LifeSemantics developed the device to improve the accessibility of pulmonary rehabilitation infrastructure for patients. In South Korea, there are around 3 million COPD patients with only about 200,000 of them receiving medical assistance.
The company plans to expand its operations in the United States with Redpill Breath, according to Kwon Hee, director of LifeSemantics’ DTx division.
Lunit to deliver AI CXR solution to top Brazilian hospital
Another South Korean company, Lunit, has signed a three-year deal to supply its AI imaging solution to one of the top hospitals in Latin America.
The Lunit INSIGHT CXR, an AI chest x-ray image analysis software, will be implemented in Hospital Israelita Albert Einstein, which runs 22 private hospitals and 29 public health facilities. It will be used in its ICU, emergency room, as well as in-patient examination rooms.
Waterdrop powers Jemincare’s digital support platform for CKD patients
Chinese insurtech Waterdrop has tied up with Jemincare to support the latter’s delivery of chronic disease management services to CKD patients.
They launched the Digital Service Platform for CKD Patients powered by the Waterdrop Patient Platform, which offers patient services outside hospitals throughout the whole disease course.
The Waterdrop platform also has a multi-dimensional operation system that provides patients with one-on-one Q&A services related to reporting interpretation, drug use, disease knowledge explanation, nutrition and lifestyle guidance, and psychological support.
AI cancer treatment software company PVMed secures $14M Series A funding
Guangzhou, China-headquartered Perception Vision Medical Technologies Co. (PVmed) has received $14 million in a Series A funding round, which was joined by investors such as Cherami Investment Group, Philips, JHF Investment, COCOCAPITAL Corporation, and Strategy Capital.
PVMed offers AI solutions that automatically process and prepare 3D CT scans and MRI data, assisting doctors in faster and more precise planning and treatment of cancers, including lung cancer, breast cancer, nasopharyngeal cancer, cervical cancer, and rectal cancer.
According to a press release, its fresh funds will be used to develop its AI cancer treatment product portfolio and ecosystem. It will also help market its AI-defined cancer and radiotherapy workflow software and hardware products to more hospitals and medtech companies.
Its software offerings, which currently cover radiotherapy, surgical oncology, and customised oncology, are now being used in more than 200 hospitals in China, processing over 200,000 cancer patients. These have also received five device certifications in China and one 510(k) approval from the US Food and Drug Administration.